O
EGRX

OppenheimerFunds’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

OppenheimerFunds’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,727
Closed -$215K – 1877
2017
Q2 		$215K Buy
+2,727
New +$223K ﹤0.01% 1797
2016
Q1 		– Sell
-68,840
Closed -$6.1M – 1744
2015
Q4 		$6.1M Buy
+68,840
New +$5.44M 0.01% 802

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

OppenheimerFunds's EGRX Position: Q3 2017 in Review

OppenheimerFunds sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017, closing a stake of 2,727 shares — an estimated $215K sold.

OppenheimerFunds first reported a position in EGRX in Q4 2015 and held it in 2 quarters. The position peaked at $6.1M in Q4 2015. 169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

  • OppenheimerFunds reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • OppenheimerFunds sold 2,727 Eagle Pharmaceuticals, Inc. shares in Q3 2017, an estimated $215K.
  • OppenheimerFunds first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
  • OppenheimerFunds's Eagle Pharmaceuticals, Inc. position peaked at $6.1M in Q4 2015.
  • 169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on OppenheimerFunds's 13F filing for Q3 2017, filed 13 Nov 2017.